SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network (PYTH) is gaining traction following its listing on Robinhood, alongside community excitement around its role as a leading oracle for Real World Assets (RWA) and its new PYTH Reserve initiative converting network revenue into token purchases. While many anticipate significant growth as an alternative to existing oracle solutions, some in the community express caution regarding future token unlocks and token concentration.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is actively discussed after achieving a $1 trillion market cap and joining the Nasdaq-100, driven by its robust e-commerce and AI initiatives. However, the community remains divided, with many celebrating its defensive strength while others question its elevated valuation amidst a broader rotation into consumer staples.

Royal Gold, Inc. engages in the business of acquiring and managing precious metal streams, royalties, and similar interests. It operates under the Acquisition and Management of Stream Interests, and Acquisition and Management of Royalty Interests segments. The Acquisition and Management of Stream Interests segment focuses on metal streams, which are purchase agreements that provide, in exchange for an upfront deposit payment, the right to purchase all or a portion of one or more metals produced, at a price determined for the life of the transaction. The Acquisition and Management of Royalty Interests segment is involved in non-operating interests in mining projects that provide the right to revenue or metals produced from the project. The company was founded by Stanley Dempsey in 1981 and is headquartered in Denver, CO.

Royal Gold, Inc.

Royal Gold is gaining significant attention as gold and silver prices reach new highs, fueling strong financial results and a wave of analyst target upgrades. The community is highlighting the company's robust royalty streaming model and strategic acquisitions, positioning it as a 'money printer' benefiting from the broader metals rally.

Pump Mind Virus is a Pure Meme with a long term vision. We are building for the future while making no promises about the present. The project aims to bring the spirit of community memes back to the Solana ecosystem. We do that with engaging content and memes. Culture through community. Viral spread by word of mouth.  And most importantly, by not using the fake hype machine that has come to dominate the meme coin landscape.

PumpMindVirus

PumpMindVirus ($PMV) is trending amidst strong community conviction that a market bottom has been established and a Solana meme season is imminent, with many anticipating significant growth. Supporters are actively discussing its 'pure meme culture' and robust community, believing it's positioned for a major breakout.

Tidal Trust II - YieldMax COIN Option Income Strategy ETF

YieldMax COIN Option Income Strategy ETF

CONY is trending amid YieldMax's recent transition to weekly distributions, a move designed to address investor demand for more frequent payouts. The community is sharply divided, with discussions revolving around whether this shift and consistent dividend reinvestment can truly offset persistent NAV erosion and the impact of recent reverse splits, especially given the volatility of its underlying asset, Coinbase.

Nova Minerals Ltd. engages in the exploration and development of mineral properties. Its projects include Estelle Gold, RPM, Korbel, Train, Stoney and Studies projects. The company was founded in January 1987 and is headquartered in Melbourne, Australia.

Nova Minerals Limited - ADR

Nova Minerals is trending as it moves to redomicile in the United States, a strategic shift anticipated to attract institutional investors and US ETFs to its Estelle Gold and Critical Minerals Project. Community enthusiasm is also driven by its key antimony resources, backed by a significant government grant for US defense needs, and an upcoming forward stock split, all fueling discussions of its long-term potential.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costco is trending as strong recent sales reports underscore its robust membership model and appeal to value-conscious consumers, fueling analyst upgrades and conversations about its premium valuation within the resilient consumer staples sector.

Lloyds Banking Group Plc is a financial services company, which engages in the provision of banking and financial services. It operates through the following segments: Retail, Commercial Banking, Insurance and Wealth, and Other. The Retail segment offers broad range of financial service products, including current accounts, savings, mortgages, motor finance and unsecured consumer lending to personal, and small business customers. The Commercial Banking segment provides a range of products and services such as lending, transactional banking, working capital management, risk management and debt capital markets services to SMEs, corporates, and financial institutions. The Insurance and Wealth segment focuses on the insurance, investment, and wealth management products and services. The Other segment refers to income and expenditure not attributed to the group’s financial reporting segments. These amounts include those arising from the group’s equities business, residual net interest income after transfer pricing, and certain gains from gilt sales. The company’s history roots are traced back to 18th century and Lloyds Banking Group was formed in January 2009 and is headquartered in London, the United Kingdom.

Lloyds Banking Group plc - ADR

Lloyds Banking Group is trending higher, fueled by recent strong financial results, a substantial dividend increase, and a new share repurchase program, alongside favorable resolution of the UK motor financing scandal. The community is noting its continued momentum to new 52-week highs, believing the stock remains undervalued compared to its peers and is now attracting wider institutional interest after surpassing key price levels.

Waystar Holding Corp. engages in the provision of healthcare organizations with mission-critical cloud software that simplifies healthcare payments. Its enterprise-grade platform streamlines the complex and disparate processes healthcare provider clients must manage to be reimbursed correctly, while improving the payments experience for providers, patients, and payers. The company was founded in 2000 and is headquartered in Lehi, UT.

Waystar Holding Corp

Waystar Holding Corp.

Waystar Holding Corp. is trending due to strong earnings and multiple analyst upgrades that highlight its AI-driven healthcare payment solutions. However, community discussions also reflect concerns over recent secondary offerings and insider selling following its IPO lock-up expiration.

BJ's Wholesale Club Holdings, Inc. engages in the operation of membership warehouse clubs. Its product categories include grocery, household and pet, television and electronics, furniture, computer and tablets, patio and outdoor living, lawn and garden, baby and kids, toys, home, health and beauty, appliances, and jewelry. The company was founded in 1984 and is headquartered in Marlborough, MA.

BJ`s Wholesale Club Holdings Inc

BJ's Wholesale Club Holdings Inc

BJ's Wholesale Club is trending as investors react to its recent mixed earnings results, where an EPS beat was tempered by a revenue miss and cautious long-term guidance, leading to price volatility. The community is actively debating if current levels present a buying opportunity, often comparing BJ's valuation and growth prospects to its peer Costco amidst the company's strategic expansion and digital initiatives.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

50,000 Shares in Novo Nordisk A/S $NVO Bought by Truffle Hound Capital LLC

Truffle Hound Capital LLC bought a new position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) during the third quarter, according to the company in its most recent disclosure with the...

Novo Nordisk A/S (NYSE:NVO) Shares Up 1.4% - What's Next?

Novo Nordisk A/S (NYSE:NVO) Shares Up 1.4% - Here's What Happened...

<ul class="summary-bullets"><li>Novo continues to battle increased compounding of its drugs, in spite of semaglutide shortage having been resolved.</li><li>Doustdar dismissed competition concerns with rival drugmaker Eli Lilly on Friday, highlighting that Novo’s oral obesity pill offers superior weight loss.&nbsp;</li><li>Reuters reported on Friday that Lilly had $1.5 billion worth of pre-launch inventory for its oral obesity drug, ensuring sufficient supply in case of simultaneous approval in several countries.</li></ul>Novo Nordisk (NVO) CEO Mike Doustdar said on Friday that the company will scale its Wegovy pills country-by-country in order to avoid a shortage or compounding of the drug.The Danish drugmaker launched the Wegovy pill, an oral obesity drug, in the U.S. in January to great reception. There are currently 246,000 people on the pill, as per the Novo CEO. &nbsp;Doustdar said on Friday in an <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.youtube.com/watch?v=UT3YKDb4WFQ">interview</a> with CNBC that the company has filed for approval in the European Union. However, the company is looking to ensure the U.S. market is supplied before choosing another country to scale in, he said, while noting that shortage in injectable semaglutide previously created an industry on the side called compounders.Novo continues to battle increased compounding of its drugs, in spite of the shortage having been resolved. Earlier this week, Novo Nordisk sued telehealth firm Hims &amp; Hers earlier this week for selling compounded versions of semaglutide, which is the active ingredient of the firm’s injectable and oral obesity drug. The company is asking the court to permanently ban the telehealth firm from selling copycat version of its drugs“So we have set ourselves, never again, on a shortage,” the CEO said.<h2 class="st-heading-2">Competition Concerns</h2>Doustdar also dismissed competition concerns with rival drugmaker Eli Lilly and Company (LLY). Lilly is expected to launch its own obesity pill in the second quarter, rivaling Novo’s Wegovy pill.Doustdar noted that the Wegovy pill yielded 16.6% weight loss in a clinical trial, compared to Lilly's 12.4%. Further the price point for the pills is likely to be similar, he said.The U.S. Food and Drug Administration is expected to decide on Lilly’s application seeking approval for its oral obesity drug Orforglipron in April. Reuters <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-builds-15-billion-stockpile-weight-loss-pill-ahead-fda-decision-2026-02-12/">reported</a> on Friday that Lilly had $1.5 billion worth of pre-launch inventory for the drug, ensuring sufficient supply in case of simultaneous approval in several countries.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVO">NVO stock</a> stayed within the ‘bearish’ territory, while message volume remained at ‘normal’ levels.Sentiment around <a href="https://stocktwits.com/symbol/LLY">LLY stock</a> trended in the ‘bearish’ territory at the time of writing.NVO stock plunged 37% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/rare-stock-slumps-on-multiple-wall-street-price-target-slashes-clinical-pipeline-uncertainty/cZR5z5FR4t4">RARE Stock Slumps On Multiple Wall Street Price Target Slashes, Clinical Pipeline Uncertainty</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Novo Nordisk To Meet Wegovy Pill Demand In US Before Expanding To Avoid Supply Shortage, Says CEO Doustdar

Novo is looking to ensure the U.S. market is supplied before choosing another country to scale in, Doustdar said in an interview with CNBC. 

Equity

Novo is looking to ensure the U.S. market is supplied before choosing another country to scale in, Doustdar said in an interview with CNBC. 


Novo Nordisk CEO on medicare coverage, new obesity pill, U.S. pricing pressure

Novo Nordisk CEO Mike Doustdar tells CNBC that Medicare coverage for obesity treatments, as well as the launch of a new obesity pill, should help boost prescription volumes and offset lower prices...

Lafayette Investments Inc. Raises Position in Novo Nordisk A/S $NVO

Lafayette Investments Inc. increased its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 44.2% during the third quarter, according to its most recent filing with the Securities and Exchange...

Caprock Group LLC Purchases Shares of 49,305 Novo Nordisk A/S $NVO

Caprock Group LLC acquired a new position in Novo Nordisk A/S (NYSE:NVO - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The...

<ul class="summary-bullets"><li>Morgan Stanley kept an ‘Overweight’ rating with a $99 target, while Raymond James reiterated a ‘Strong Buy’ with a $118 target.</li><li>Raymond James tied Viking’s oral VK2735 to strong early demand for Novo Nordisk’s newly launched Wegovy tablet.</li><li>Viking plans to start Phase 3 trials for oral VK2735 in Q3 2026 after encouraging mid-stage weight-loss data.</li></ul>Shares of Viking Therapeutics (VKTX) are back on traders’ radar as Wall Street pointed to nearly 300% upside in the stock, positioning its oral obesity pill as a potential beneficiary of the strong early uptake seen in Novo Nordisk’s newly launched Wegovy tablet.&nbsp;<a href="https://stocktwits.com/symbol/VKTX">VKTX stock</a> jumped nearly 7% on Thursday to hit its highest level in over three weeks, and extended gains slightly after-hours.&nbsp;<h2 class="st-heading-2">Wall Street View On VKTX</h2>Morgan Stanley lowered its price target to $99 from $102 and maintained an ‘Overweight’ rating, implying a 225% upside from the stock’s last close.Raymond James cut its target to $118 from $122 and reiterated a ‘Strong Buy’ rating, implying a 287% upside from current levels. The firm pointed to Novo Nordisk’s early oral obesity pill prescription data as a sign of demand for pill-based GLP-1 therapies, according to a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.investing.com/news/analyst-ratings/viking-therapeutics-stock-price-target-lowered-to-118-by-raymond-james-93CH-4502540">report</a> by Investing.It also cited Viking’s late-stage subcutaneous and oral VK2735 programs and its amylin agonist expected to enter clinical testing later this year.&nbsp;<h2 class="st-heading-2">Novo’s Wegovy Pill Highlights Oral Demand</h2>Earlier this month, Novo Nordisk said demand for its oral Wegovy pill got off to a strong start after launching in the U.S. in early January. By January 23, less than three weeks post-launch, about 50,000 prescriptions were being filled weekly, with more than 170,000 patients on therapy.&nbsp;Mike Doustdar said more than 240,000 people in the U.S. have already begun taking the medication, calling it one of the most successful rollouts in the industry. To meet rising demand, Novo is&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-looks-to-ireland-to-scale-production-of-wegovy-pill-report/cZRT0F6R4rc">expanding manufacturing</a> at its facility in Athlone, Ireland, to supply markets outside the U.SRoughly 90% of prescriptions were paid out of pocket, and most were for the starter dose. On an investor call, Novo Nordisk U.S. President David Moore said early uptake was more than twice that of any prior U.S. weight-loss drug launch and that most prescriptions appeared to be from patients new to these medications. The starter dose is priced at $149 per month in cash, compared with about $349 per month for the injectable version.<h2 class="st-heading-2">Oral Obesity Pill Advances Toward Phase 3&nbsp;</h2>Viking said that it plans to initiate Phase 3 development of oral VK2735 in the third quarter of 2026, following an end-of-Phase 2 meeting with the FDA.In a mid-stage clinical study of its oral obesity pill, Viking said patients lost as much as 12.2% of their body weight in just 13 weeks.&nbsp;Viking also pointed to follow-up data showing that patients continued to lose weight even after their dose was reduced. The company said the drug stays active in the body for longer than many alternatives, which could allow more flexible dosing and make it easier for patients to switch between the pill and the injectable version without changing drugs, since both use the same active compound.<h2 class="st-heading-2">Maintenance Dosing Data Set For 2026</h2>The subcutaneous version of VK2735 is being evaluated in the Phase 3 Vanquish program. Vanquish-1 has completed enrollment ahead of schedule, while Vanquish-2 is nearing full enrollment. Both studies assess percent change in body weight after 78 weeks.Viking has also completed enrollment in a Phase 1 maintenance dosing study evaluating monthly, biweekly and weekly injections, as well as daily and weekly oral regimens. Results are expected in the third quarter of 2026. The company recently completed a bioequivalence study to support an auto-injector and plans to introduce it into the Vanquish program this quarter.<h2 class="st-heading-2">VKTX Q4 Review&nbsp;</h2>For the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/vktx-stock-rallies-after-hours-on-optimism-around-companys-obesity-portfolio/cZb6MYxR4Ak">fourth quarter</a> of 2025, Viking reported a loss of $1.38 per share, driven by higher research and development spending. Full-year R&amp;D expenses rose to $345 million as multiple late-stage programs advanced.Viking ended 2025 with $706 million in cash, cash equivalents and short-term investments, which the company said is sufficient to fund ongoing Phase 3 trials, maintenance data readouts and the planned oral Phase 3 program.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for VKTX, long a favorite among biotech investors for takeover speculation, was ‘bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/vktx_ss_png_2ef5c92e34.webp" alt="vktx ss.png" width="970" height="146"><figcaption>VKTX sentiment and message volume as of February 12 | Source: Stocktwits</figcaption></figure>One user said big pharma is now far more selective on obesity deals, suggesting only those willing to pay a “massive” premium will move once drug differences are clear. “Been in VK for years and been best biotech outcome for me”<stembedurl>https://stocktwits.com/biolover/message/644873965</stembedurl>Another user said, “Maintenance dosing trial (Q3 2026) should offer us a very good opportunity to re-rate the stock price upward.”<stembedurl>https://stocktwits.com/DG20/message/644872502</stembedurl><a href="https://stocktwits.com/symbol/VKTX">VKTX stock</a> has risen 4% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Viking Therapeutics, Inc., in front of a screen showing the company's latest stock market chart on July 19, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout?

The company ended 2025 with $706 million in cash, which it said is enough to fund ongoing Phase 3 trials and maintenance data readouts.

Novo Nordisk Plans Wegovy Vial Launch To Counter Eli Lilly, Target Broader Obesity Market

Novo Nordisk plans to sell Wegovy in vials in the U.S., expanding options as it competes with Eli Lilly in the growing weight-loss drug market.read more...

How to Play Eli Lilly Stock Following a Robust Q4 Earnings Report

LLY's Q4 beat and bold 2026 outlook highlight surging GLP-1 sales and a deep obesity pipeline. 

Savvy Advisors Inc. Purchases 22,138 Shares of Novo Nordisk A/S $NVO

Savvy Advisors Inc. grew its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 83.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and...

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

NVO
Novo Nordisk A/S

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest NVO News

NVONovo Nordisk A/S